1625 Results (Page 38 of 65)
Rare Diseases Markets Research Reports
Italy Guillain-Barre Syndrome (GBS) Therapeutics Market Analysis
Italy Guillain-Barre Syndrome (GBS) Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. Guillain Barre Syndrome is a rare autoimmune disorder in which persons immune system attacks nervous system. The market for Guillain-Barre Syndrome (GBS) drugs is growing rapidly as a result of increase in the incidence and prevalence of the guillain-barre syndrome, advancements in technology and development in healthcare, support and funding by governments globally, rise in the geriatric population and increase in the prevalence of chikungunya and immune diseases like multiple sclerosis , increase in the approvals of immunoglobulins by regulatory bodies and increase in research and development activities by pharmaceutical companies. Alexion Pharmaceuticals Inc., Annexon Inc., Cellenkos Inc., Cresence AS, Akari Therapeutics Plc, Chugai Pharmaceutical Co Ltd are the key market players operating in global gullian barre syndrome drugs market.
China Ovarian Cancer Therapeutics Market Analysis
China Ovarian Cancer Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. One of the key factors driving the growth of the ovarian cancer market is the rising prevalence of the disease. Other important drivers are the development of new therapies and treatments, rising healthcare expenses, and increased government support. Due to greater public awareness of healthcare issues, the market for ovarian cancer is also expanding. Major global players in Ovarian Cancer Therapeutics Market are Allergan Plc, AstraZeneca, F. Hoffmann-La Roche Ltd, Pfizer Inc., Merck KGaA, Syndax, Clovis Oncology, Boehringer Ingelheim International GmbH., GlaxoSmithKline plc., Exelixis, Inc., KINTARA THERAPEUTIC, INC., Bristol-Myers Squibb Company, Novartis AG, Johnson & Johnson Private Limited, AbbVie Inc.
Japan Eosinophilic Esophagitis Drugs Market Analysis
Japan Eosinophilic Esophagitis Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for eosinophilic esophagitis drugs is growing rapidly as a result of increase in awareness programs for disorders associated with eosinophils, development and use of new generation of non- invasive diagnostic tools, increase in use of eosinophilic esophagitis drugs and therapies for the treatment of various inflammations by physicians worldwide, increase in research and development activities and clinical trials conducted by pharmaceutical firms, promising eosinophilic esophagitis pipeline. Astra Zeneca, Sanofi, Cipla, Glaxo smith kline ,Arena pharmaceuticals, Takeda pharmaceuticals are the top key market players operating in the global eosinophilic esophagitis drugs market.
Brazil Pyruvate Kinase (PK) Deficiency Market Analysis
Brazil Pyruvate Kinase (PK) deficiency market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Pyruvate Kinase (PK) deficiency is growing rapidly as a result of increase in incidence and prevalence of disease, increased awareness about the disease, improved diagnostic techniques, advancements in treatment options, increase in research and development and rise in patient assistance programmes. Agios pharmaceuticals, Pfizer Inc., Sanofi, Novartis, Teva Pharmaceutical Industries Ltd, Green cross corporation are the top key market players operating in the global Pyruvate Kinase (PK) deficiency market.
US Hodgkins Lymphoma Drugs Market Analysis
US Hodgkins Lymphoma Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030.The market for Hodgkins Lymphoma Drugs is rising due to Increasing incidence of Hodgkin lymphoma, Extensive research and development activities, Growing adoption of immunotherapies, Increasing awareness and diagnosis about disease, Improved reimbursement policies and increased insurance coverage for cancer treatments along with growing availability of targeted therapies and combination therapies for Hodgkin Lymphoma Drugs. Bristol Myers Squibb, Merck & Co., Inc. (MSD), Takeda Pharmaceutical Company Limited, Roche Holding AG, Novartis AG, Pfizer Inc., AstraZeneca plc, Johnson & Johnson, AbbVie Inc., Celgene Corporation (a subsidiary of Bristol Myers Squibb), Amgen Inc., Gilead Sciences, Inc. are the global companies in Hodgkins Lymphoma Drugs market.
Germany Angelman Syndrome Therapeutics Market Analysis
Germany During the forecast period of 2023?2030, The Angelman Syndrome Therapeutics Market is anticipated to increase from $xx Mn in 2023 to $xx Mn by 2030, recording a CAGR of xx percent. An uncommon inherited neuro-developmental condition called Angelman Syndrome is marked by a severe developmental delay, sleep issues, jerky movements, and a lot of laughter. As the illness is more common, there are more government measures to manage it. This has also helped with research and development for condition treatment. These factors collectively represent the Angelman Syndrome Therapeutics Market's driving forces. Boston Children's Hospital, the Angelman Syndrome Foundation, Rady Children's Hospital in San Diego, General Hospital Corporation, Cincinnati Children's Hospital Medical Center, and others are major competitors in the market for treating Angelman syndrome.
Italy Hemophilia A Therapeutics Market Analysis
Italy Hemophilia A Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. A lack of or failure with regard to clotting factor VIII characterises the rare inherited bleeding condition known as haemophilia A. It is the most prevalent form of haemophilia and primarily affects men, though it can also afflict women who carry the gene mutation. Hemophilia A market development goes beyond traditional markets, with a stronger emphasis on increasing access to care in developing markets. In areas where access to specialised care and therapies may be restricted, efforts are being made to improve diagnosis, treatment infrastructure, and pricing. Some of the notable companies operating in the Hemophilia A therapeutics market include BioMarin Pharmaceutical Inc, Bayer AG, Pfizer Inc., Novo Nordisk A/S, F. Hoffmann-La Roche Ltd., Shire (now part of Takeda Pharmaceutical Company Limited), CSL Behring LLC, Sanofi S.A., Grifols S.A. and Octapharma AG.
Japan Erythropoietin Drugs Market Analysis
Japan Erythropoietin Drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for erythropoietin drugs is growing rapidly as a result of rising prevalence of chronic diseases like kidney diseases, cancer, HIV globally and requirements of erythropoietin drugs in these diseases, rise in anemia in patients, growing awareness about blood related disorders like anemia, patent expiration of innovator drugs and development of generic drugs, development of erythropoietin biosimilars and therapeutic benefits offered by erythropoietin drugs. Johnson & Johnson, Inc., LG Life Sciences Ltd., Ranbaxy Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., F. Hoffman-La Roche Ltd., Celltrion, Inc., and Biocon Limited are the key market players operating in global erythropoietin drugs market.
Brazil Rare Hematology Disorders Market Analysis
Brazil Rare Hematology Disorders market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Rare Hematology Disorders is growing rapidly as a result of increase in incidence of rare blood disorders, increase in awareness of rare hematology disorders, advancement in genetic testing and diagnostic techniques, increase in spending on healthcare infrastructure and increasing adoption of gene therapy. Sanofi Genzyme, Pfizer Inc., Novartis AG, Alexion Pharmaceuticals, Shire., BioMarin Pharmaceutical Inc., CSL Behring are the key global market players operating in rare hematology disorders market.
US Huntington's Disease Drugs Market Analysis
US Huntington's Disease Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The market for treating Huntington's disease is expanding due to a number of causes, including an increase in the disease's prevalence and a rise in the demand for modern drug types to treat the signs and symptoms of the disease especially rise in disease modifying therapies, incentives provided by regulatory authorities like orphan drug designations. Some of the key players in the global Huntington's Disease Drugs Market include Pfizer, Inc. Alnylam Pharmaceuticals Inc. Teva Pharmaceutical Industries Ltd. Neurocrine Biosciences, Inc. Ionis Pharmaceuticals, Vertex Pharmaceuticals Incorporated (U.S.), Elekta AB (Sweden), Alterity Drugs(Australia) and som biotech (spain).
Germany Ankylosing Spondylitis Therapeutics Market Analysis
Germany Ankylosing Spondylitis Drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. Ankylosing spondylitis is a kind of arthritis that affects connective tissues. The sacroiliac joints, which connect the spine to the pelvis, become inflamed, but in extreme situations, the spine's bones might fuse together and become very inflexible. A rough estimate of 1.1 Mn Americans, or one out of every 200 adults, are impacted. Abbvie, Amgen, Eli Lilly, Janssen, Merck, Pfizer, Novartis, UCB, and many other leading companies are active in the ankylosing spondylitis global market. To increase their market share, these businesses engage in strategic alliances and acquisitions in addition to concentrating on research and development to bring novel therapies to market.
Italy Hemophilia B Therapeutics Market Analysis
Italy Hemophilia B Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The rare genetic bleeding illness known as haemophilia B is brought on by a lack of or malfunction in the clotting factor IX. The increasing prevalence of haemophilia B, improvements in available treatments, and greater public knowledge of the condition have all contributed to the steady growth of the global market for therapies for the condition. However, because Hemophilia B is less common than Hemophilia A, the market for therapies for this condition is smaller than it is for Hemophilia A. Takeda Pharmaceutical Company Limited (previously Shire), Takeda Pharmaceutical Company Inc., Pfizer Inc., F. Hoffmann-La Roche Ltd., Novo Nordisk A/S, CSL Behring LLC, Sanofi S.A., Grifols S.A., Octapharma AG, and others are notable market participants.
China Phenylketonuria Therapeutics Market Analysis
China Phenylketonuria Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The market for phenylketonuria therapeutics is being driven by a variety of factors, including the increasing prevalence of PKU, technological advancements in PKU diagnostics, government initiatives and funding, and growing patient demand for effective treatments for the condition. Major global players in Phenylketonuria Therapeutics Market are DAIICHI SANKYO COMPANY, LIMITED, Ajinomoto Cambrooke, Inc., American Gene Technologies, Ultragenyx Pharmaceutical, Nutricia, Homology Medicines, Inc., Reckitt Benckiser Group plc, Abbott, Travere Therapeutics, Inc., Synlogic, Promin., SOM BIOTECH, S.L. Healthcare, Synthetic Biologics, Inc., Nestl?, Codexis, BioMarin, Erytech Pharma.,
Japan Fabry Disease Drugs Market Analysis
Japan Fabry disease drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for fabry disease drugs is growing rapidly as a result of increase in incidence and prevalence of fabry disease globally, increase in awareness about the disease globally, better diagnosis rates, improved access to treatment, development of new emerging therapies, orphan drug designations provided by regulatory body?s, increase in stratergic collaborations, rise in research and development activities and approval of promising pipeline products. Chiesi Farmaceutici SpA , Sanofi, Shire ,Takeda Pharmaceutical Company Limited, Amicus Therapeutics, Inc., JCR Pharmaceuticals, Moderna are the key market players operating in global fabry disease drugs market.
Brazil Rare Hemophilia Factors Market Analysis
Brazil Rare Hemophilia Factors market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Rare Hemophilia Factors is growing rapidly as a result of growing incidence of rare hemophilia factors deficiency, rising adoption of prophylactic treatments, growing awareness about rare hemophilia factors and their treatment options, rising demand for better and more effective therapies for rare hemophilia factors. Baxter, Bayer AG, Bio Products Laboratory Ltd., Novo Nordisk A/S, Alexion Pharmaceuticals, Amgen Inc, BioMarin, Amgen Inc are the key global market players operating in rare hemophilia factors market.
US Leukocyte Adhesion Deficiency (LAD-I) Market Analysis
US Leukocyte Adhesion Deficiency (LAD-I) therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. An uncommon genetic condition called leukocyte adhesion deficiency (LAD-I) impairs the immune system's capacity to combat infections. There is currently no cure for LAD-I, and there are few effective treatments available. To fill this unmet medical need, new medicines are becoming more and more popular. Vertex Pharmaceuticals, Orpha Labs, Avalo Therapeutics, Inc., Rocket Pharmaceuticals, Inc., Aspen Neuroscience, Magenta Therapeutics, Rubius Therapeutics, Enochian Biosciences, Sana Biotechnology, and Sigma-Aldrich are major global players.
Germany Uveitis Therapeutics Market Analysis
Germany Uveitis therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Uveitis is an inflammation of the uvea, which is the middle layer of the tissue that surrounds the eye and is made up of the iris, ciliary body, and choroid. The most typical extra-articular Spondyloarthritis symptom is uveitis (SpA) Increased healthcare financing, together with the development of drugs with improved efficacy and fewer side effects, has benefited technological advancements in the field, which together are serving as a potential driver of the uveitis therapeutic market. Several well-known companies involved in the development and marketing of uveitis medicines include Novartis AG, Bausch Health Companies Inc., Santen Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., Johnson & Johnson, AbbVie Inc., and Allergan (now a division of AbbVie).
Italy Hepatorenal Syndrome Therapeutics Market Analysis
Italy Hepatorenal Syndrome Therapeutics (HRS) Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. People with cirrhosis or acute liver failure who develop kidney impairment are said to have hepatorenal syndrome (HRS), a serious consequence of advanced liver disease. Renal function improvement and halting further decline are the main objectives of treatment for hepatorenal syndrome. The market for HRS Therapeutics is being driven by an increase in the number of patients with liver illnesses, ongoing medical technology breakthroughs, government efforts, and partnerships and collaborations amongst pharmaceutical companies. Ferring Pharmaceuticals, Hospira, Pfizer, Sandoz, Novartis, Grifols, CSL Behring, Octa pharma, and Baxalta are major international participants in the market for treatments for hepatocellular syndrome.
China Primary Biliary Cholangitis (PBC) Therapeutics Market Analysis
China Primary Biliary Cholangitis (PBC) Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Due to a variety of critical variables, including growing public awareness of rare diseases, improving healthcare infrastructure, high disposable income, and government backing for cutting-edge autoimmune disease treatments, the market for primary biliary cholangitis treatments is booming.Major global players in Primary Biliary Cholangitis (PBC) Therapeutics Market are Actavis, Inc.; Epic Pharma, LLC; Mylan Pharmaceuticals, Inc.; Teva Pharmaceuticals; Glenmark Pharmaceuticals, Ltd.; Par Pharmaceutical, Inc.; Intercept Pharmaceuticals, Inc
Japan Fibrodysplasia Ossificans Progressiva Drugs Market Analysis
Japan Fibrodysplasia Ossificans Progressiva Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The market for Fibrodysplasia Ossificans Progressiva Drugs is expanding as a result of growing incidence and prevalence of fibrodysplasia ossificans progressiva , increase in the number of R&D activities, increase in Partnerships and Collaborations between market players. Pfizer Inc., AstraZeneca, Limited, Regeneron Pharmaceuticals, Inc, Clementia Pharmaceuticals, Novartis are the top key market players operating in the global Fibrodysplasia Ossificans Progressiva Drugs market.
Brazil Rett Syndrome Drugs Market Analysis
Brazil Rett Syndrome Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The market for Rett syndrome will grow over time as a result of expanding female population, rising public healthcare programme spending for patient advocacy and rising global healthcare expenditure. Major global players in Rett Syndrome Drugs Market are Merck KGaA (Germany), Eisai Co., Ltd. (Japan), AstraZeneca (U.K.), Sanofi (France), Novartis AG (Switzerland), Abbott (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Teva Pharmaceutical Industries Ltd. (Ireland), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), WOCKHARDT (Mumbai), Novo Nordisk A/S (Denmark), Glenmark Pharmaceuticals Limited (India), Cipla Inc. (U.S.), Bausch Health Companies Inc. (Canada), Otsuka America Pharmaceutical, Inc. (U.S.), Johnson & Johnson Private Limited (U.S.), Takeda Pharmaceutical Company Limited (Japan), Sumitomo Corporation (Japan), Biocon (India)
US Lysosomal Storage Disorders Drugs Market Analysis
US Lysosomal Storage Disease Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The rise in lysosomal diseases, greater public awareness of unusual lysosomal storage disorders, increased research and development for diagnostics, and increased drug development for treating lysosomal diseases are the main drivers impacting the market for lysosomal storage disease treatments. Major global players in Lysosomal Storage Disease Drugs Market are Pfizer Inc, Takeda Pharmaceutical Company Limited (Shire Plc), Sanofi (Genzyme Corporation), BioMarin, Johnson & Johnson (Actelion Pharmaceuticals Ltd), Amicus Drugs, Inc, Alexion Pharmaceuticals, Inc, Sigilon Drugs, Inc, and Orphazyme A/S are some of the companies that participate in this industry.
Germany Anthrax Therapeutics Market Analysis
Germany Anthrax therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Bacillus anthracis is the bacteria that causes anthrax (B. anthracis). The market for anthrax therapeutics is fueled by factors such the increased prevalence of bacterial infections, rising research funding, the development of innovative medicines for treating anthrax, and pipeline goods, which increase demand and stimulate market expansion. The current rise in healthcare spending in both developed and developing nations is anticipated to give manufacturers a competitive edge in the development of novel and ground-breaking products. Global industries in the Anthrax therapeutics market are Aristo Pharmaceuticals Private Limited, Indoco Remedies Ltd., Lupin, Deinove, Bayer AG, Pfizer Inc., Emergent, Soligenix, Zydus Group, Sanofi, Alembic Pharmaceuticals, Emergent, Sanofi, Porton Biopharma, Lupin, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd and many more
Italy Hereditary Angioedema Therapeutics Market Analysis
Italy Hereditary Angioedema Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. A uncommon genetic condition known as hereditary angioedema (HAE) is characterised by recurrent episodes of swelling in different body areas. It is brought on by a lack or malfunction of certain proteins involved in controlling the immune response. The regulatory authorities have designated numerous HAE therapies as orphan drugs as a result of this classification, pharmaceutical companies are given some incentives including financial advantages and prolonged exclusivity, which may promote investment in HAE R&D. The increasing prevalence and diagnosis of HAE around the world have been driving the growth of the global market for HAE therapies. This trend offers pharmaceutical businesses the chance to increase their market share, make research and development investments, and introduce novel treatments to various geographic areas. Hereditary angioedema therapies are being developed and produced by a number of international pharmaceutical companies (HAE). Takeda Pharmaceutical Company Limited, Inc., CSL Behring, Pharming Group NV, Ionis Pharmaceuticals, Pharvaris, Dyax Corp., Shire (now a part of Takeda), Attune Pharmaceuticals, Prometic Life Sciences Inc., KalVista Pharmaceuticals, and Biocryst are some of these organisations.
Japan Freidreich's Ataxia Market Analysis
Japan Freidreich?s Ataxia market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Freidreich?s Ataxia is growing rapidly as a result of increase in research and developmental activities for diagnosis and treatment of freidreich?s ataxia, collaborations between academic institutions and industry partners and incentives provided in orphan drug designation by regulatory authorities. PTC Therapeutics, Design Therapeutics, Aurobindo Pharma Ltd., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Larimar Therapeutics, Inc., Jupiter Neurosciences, Inc., Lexeo Therapeutics, Zydus Lifesciences Ltd., Cipla Limited, GlaxoSmithKline Plc., Reata Pharmaceuticals, Inc., and Retrotope Inc. are the key global market players operating in global freidreich?s Ataxia Market.
